StockNews.com upgraded shares of Compugen (NASDAQ:CGEN – Get Rating) from a sell rating to a hold rating in a research note published on Tuesday morning.
CGEN has been the subject of a number of other research reports. JMP Securities reduced their target price on Compugen from $8.00 to $4.00 and set a market outperform rating for the company in a report on Monday, August 8th. Jefferies Financial Group lowered Compugen from a buy rating to a hold rating and set a $2.00 price objective for the company. in a report on Friday, August 5th. Truist Financial cut their price objective on Compugen from $14.00 to $4.00 and set a buy rating for the company in a report on Tuesday, August 23rd. Finally, Oppenheimer cut their price objective on Compugen from $14.00 to $12.00 and set an outperform rating for the company in a report on Monday, August 8th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Compugen currently has a consensus rating of Moderate Buy and an average price target of $6.20.
Get
Compugen alerts:
Compugen Stock Performance
Shares of NASDAQ:CGEN opened at $0.91 on Tuesday. The stock has a fifty day moving average of $1.41 and a 200-day moving average of $2.04. The company has a market capitalization of $79.02 million, a PE ratio of -2.34 and a beta of 2.15. Compugen has a one year low of $0.91 and a one year high of $7.48.
Compugen (NASDAQ:CGEN – Get Rating) last released its earnings results on Thursday, August 4th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.01. During the same period in the previous year, the business posted ($0.11) earnings per share. As a group, research analysts forecast that Compugen will post -0.43 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Taylor Frigon Capital Management LLC increased its holdings in shares of Compugen by 1.9% in the first quarter. Taylor Frigon Capital Management LLC now owns 672,055 shares of the biotechnology company's stock valued at $2,164,000 after purchasing an additional 12,769 shares in the last quarter. Eagle Rock Investment Company LLC acquired a new stake in Compugen during the 4th quarter worth $83,000. Qube Research & Technologies Ltd acquired a new stake in Compugen during the 1st quarter worth $85,000. WMS Partners LLC acquired a new stake in Compugen during the 1st quarter worth $74,000. Finally, Antonetti Capital Management LLC grew its holdings in Compugen by 41.5% during the 1st quarter. Antonetti Capital Management LLC now owns 350,671 shares of the biotechnology company's stock worth $1,129,000 after acquiring an additional 102,771 shares during the period.
About Compugen
(Get Rating)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.
See Also
- Get a free copy of the StockNews.com research report on Compugen (CGEN)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
